Planned
EXS21546-002
Fase 1/2 - advanced solid tumors NSCLC + RCC
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
Ongoing
MK6482 - 011
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After 1 Prior Anti-PD-1/L1 Combination Regimen
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04586231
Closed
CHECKMATE 214 CA209-214
A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, advanced or metastatic renal cell carcinoma
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT02231749
IMMOTION WO39210
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03024996
MK6482 – 013
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
- Principal investigator : Prof. Dr. Benoit Beuselinck
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04489771